Clinical Trials
12 trialsNCT05068102 2026-05-27
A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab
Boehringer Ingelheim
Phase 1 Active not recruiting
NCT03778229 2026-04-23
SAVANNAH
AstraZeneca
Phase 2 Active not recruiting
NCT06595498 2026-03-02
Next Generation Sequencing Method for the Detection of EGFR Gene Mutations in the Plasma of Patients With Lung Cancer
Istituto Oncologico Veneto IRCCS
Phase NA Active not recruiting
NCT04606771 2026-02-27
CoC
AstraZeneca
Phase 2 Active not recruiting
NCT04198766 2025-12-18
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Inhibrx Biosciences, Inc
Phase 1/2 Active not recruiting
NCT03703297 2025-11-21
ADRIATIC
AstraZeneca
Phase 3 Active not recruiting
NCT05812027 2025-11-17
A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors
TScan Therapeutics, Inc.
Active not recruiting
NCT03519971 2025-10-28
Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer
AstraZeneca
Phase 3 Active not recruiting
NCT04035486 2025-10-10
FLAURA2
AstraZeneca
Phase 3 Active not recruiting
NCT04603287 2025-09-26
A Study of SI-B001, an EGFR/HER3 Bispecific Antibody, in Locally Advanced or Metastatic Epithelial Tumors
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1 Active not recruiting
NCT03800134 2025-06-11
AEGEAN
AstraZeneca
Phase 3 Active not recruiting
NCT05818449 2024-06-04
DigiNet
University of Cologne
Phase NA Active not recruiting